ArticleWorld journal of surgical oncology2025
Prognostic impact of albumin-bilirubin score in predicting the long-term survival of distal cholangiocarcinoma after radical surgery.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Albumin-Bilirubin Score (ALBI) serves as an indicator of nutritional status and is a widely recognized prognostic biomarker in cancer patients. The purpose of this research is to evaluate the association between ALBI and survival outcomes in patients with distal cholangiocarcinoma (dCCA) after radical surgery, and develop a nomogram model based on the ALBI to predict individual survival.
methodsA total of 177 individuals with dCCA receiving surgery from Jan 2011 to Jan 2022 were enrolled in the research. The association between ALBI and clinicopathologic factors was investigated. The impact of ALBI on recurrence-free survival (RFS) and overall survival (OS) was evaluated by Kaplan-Meier curves and Cox proportional hazards models. Nomograms based on ALBI and other prognostic variables screened by multivariate analysis were produced in predicting RFS and OS of dCCA patients following radical surgery, and the nomograms were evaluated by the consistency index (C-index), calibration curve and decision curve analysis (DCA) curve.
resultsThe optimal cut-off value for ALBI was -1.67, and the area under the ROC curve (AUC) was 0.71. The High-ALBI group had a considerably shorter RFS and OS (P < 0.001). Multivariate analysis revealed that the ALBI, degree of differentiation, portal vein invasion, and lymph node invasion were significant prognostic factors for RFS, and that the ALBI, CA19-9, degree of differentiation, lymph node invasion, and portal vein invasion were significant prognostic factors for OS. The nomograms were constructed based on these significant prognostic factors. The calibration curves displayed good consistency between actual and predicted probability. Nomograms based on these variables have better discriminant ability in predicting RFS and OS compared with the American Joint Committee on Cancer (AJCC) TNM stage. Moreover, the scores predicted by the nomogram enabled patient stratification into low-points and high-points groups. Kaplan-Meier curves demonstrated that patients in the high-points group had considerably better prognoses than those in the low-points group (p < 0.001).
conclusionALBI was an independent prognostic factor in predicting RFS and OS of dCCA patients after radical surgery. The nomograms based on ALBI can provide reliable, personalized survival prediction for dCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.